“Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals.”, Vaccine, vol. 36, no. 6, pp. 881-889, 2018.
, “Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.”, Vaccine, vol. 33, no. 39, pp. 5225-34, 2015.
, “Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.”, Science, vol. 373, no. 6561, pp. 1372-1377, 2021.
, “Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.”, JAMA, vol. 314, no. 3, pp. 237-46, 2015.
, “A Genetically Engineered Plasmodium Falciparum Parasite Vaccine Provides Protection from Controlled Human Malaria Infection”, Sci Transl Med, vol. 14, no. 659, p. eabn9709, 2022.
, “Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.”, Vaccine, vol. S0264-410X, no. 20, pp. 31504-31508, 2021.
, “Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.”, J Infect Dis, vol. 206, no. 6, pp. 811-20, 2012.
, “Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women.”, J Infect Dis, vol. 204, no. 6, pp. 854-63, 2011.
, “Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.”, JAMA, vol. 312, no. 14, pp. 1420-8, 2014.
, “An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.”, N Engl J Med, 2020.
, “PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection.”, PLoS Pathog, vol. 17, no. 5, p. e1009594, 2021.
, “Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.”, Vaccine, vol. 30, no. 28, pp. 4240-8, 2012.
, “Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.”, Vaccine, vol. 36, no. 5, pp. 606-614, 2018.
, “Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women.”, Vaccine, vol. 36, no. 31, pp. 4663-4671, 2018.
, “Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.”, Vaccine, vol. 35, no. 13, pp. 1675-1682, 2017.
, “Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old.”, J Infect Dis, vol. 212, no. 4, pp. 552-61, 2015.
, “Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.”, J Infect Dis, vol. 203, no. 5, pp. 666-73, 2011.
, “Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.”, N Engl J Med, 2020.
, “Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women.”, Vaccine, vol. 36, no. 52, pp. 8054-8061, 2018.
, “Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial.”, JAMA, vol. 311, no. 17, pp. 1760-9, 2014.
, “Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants.”, Vaccine, vol. 38, no. 33, pp. 5355-5363, 2020.
,